Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-1221 vs Myozyme/Lumizyme in Late-Onset Pompe Disease
NCT02898753Phase 2Terminated
- Sponsor
- Valerion Therapeutics
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Replacement Enzymes, Fc-Fusion Proteins
- Countries
- 2
01
Overview
A Phase 2 trial of clervonafusp alfa in Pompe disease, sponsored by Valerion Therapeutics. Started Jun 2017; status: terminated.
02
Drugs
clervonafusp alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT02898753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02898753.